- Home
- TORO vs RPTX Comparison
TORO vs RPTX Comparison
Compare TORO & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- RPTX
- Stock Information
- Founded
- TORO 2022
- RPTX 2016
- Country
- TORO Cyprus
- RPTX Canada
- Employees
- TORO N/A
- RPTX 129
- Industry
- TORO Marine Transportation
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- RPTX Health Care
- Exchange
- TORO Nasdaq
- RPTX Nasdaq
- Market Cap
- TORO 40.3M
- RPTX 38.3M
- IPO Year
- TORO N/A
- RPTX 2020
- Fundamental
- Price
- TORO $1.95
- RPTX $1.20
- Analyst Decision
- TORO
- RPTX Strong Buy
- Analyst Count
- TORO 0
- RPTX 3
- Target Price
- TORO N/A
- RPTX $4.50
- AVG Volume (30 Days)
- TORO 62.6K
- RPTX 448.7K
- Earning Date
- TORO 04-15-2025
- RPTX 05-06-2025
- Dividend Yield
- TORO N/A
- RPTX N/A
- EPS Growth
- TORO N/A
- RPTX N/A
- EPS
- TORO 1.09
- RPTX N/A
- Revenue
- TORO $22,394,283.00
- RPTX $53,477,000.00
- Revenue This Year
- TORO N/A
- RPTX N/A
- Revenue Next Year
- TORO N/A
- RPTX $7.14
- P/E Ratio
- TORO $1.81
- RPTX N/A
- Revenue Growth
- TORO 0.40
- RPTX 4.58
- 52 Week Low
- TORO $1.70
- RPTX $0.89
- 52 Week High
- TORO $4.85
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- TORO 39.45
- RPTX 62.88
- Support Level
- TORO $1.70
- RPTX $0.89
- Resistance Level
- TORO $2.08
- RPTX $1.02
- Average True Range (ATR)
- TORO 0.24
- RPTX 0.08
- MACD
- TORO -0.01
- RPTX 0.03
- Stochastic Oscillator
- TORO 28.09
- RPTX 72.09
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.